With our strong foundation in research, teaching and innovative clinical care, OSF HealthCare Cardiovascular Institute continues to be a leader in the field of cardiovascular medicine. We remain focused on our goals of providing a best-class patient experience while demonstrating superior outcomes.


For over 30 years, the research department at OSF HealthCare Cardiovascular Institute has participated in research trials at our Peoria and Rockford offices. The research trials study cardiovascular medications and/or devices in general cardiology, interventional cardiology, electrophysiology, heart failure, vascular care and cardiothoracic care.

Many of our research trials are sponsored by international drug and device companies, while other trials are initiated by OSF HealthCare Cardiovascular Institute providers.

All of our studies are approved by the Peoria Institutional Review Board (IRB) at the University of Illinois College of Medicine. The IRB is an ethical review board who protects human rights for those participating in research trials.

OSF HealthCare Cardiovascular Institute is proud to contribute to medical science through our trials and be a part of many state-of-the-art treatments being approved by the Food and Drug Administration (FDA). Through our research, we are able to deliver the most appropriate and advanced treatment options to our patients.

Medication Trials

  • A-DUE

  • A-DUE: Efficacy and safety of Macitentan and Tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension (PAH), followed by an open-label treatment period with Macitentan and Tadalafil fixed dose combination therapy.


  • AEGIS II: Efficacy and safety of CSL112 in subjects with Acute Coronary Syndrome.

  • CLEAR Outcomes

  • CLEAR Outcomes: A randomized study to assess the effect of Bempedoic Acid on the occurrence of major Cardiovascular events in patients with, or at high risk for, Cardiovascular Disease who are Statin Intolerant.


  • DIAMOND: Patiromer for the management of Hyperkalemia in subjects receiving Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) medications for the treatment of HF

  • EMPEROR Preserved

  • EMPEROR Preserved: A randomized trial to evaluate the safety and efficacy of once daily empagliflozin 10 mg compared to placebo, in patients with HFpEF.


  • PARAGLIDE HF: Effects of Entresto vs Valsartan on changes in NT-proBNP and outcomes, safety, and tolerability in HFpEF patients with acute decompensated heart failure who have been stabilized during hospitalization and initiated in-hospital or within 30 days post-discharge.


  • PRESERVED HF: Effects of Dapagliflozin on biomarkers, symptoms and functional status in patients with HFpEF.


  • PROACT Xa: A randomized study to determine if patients with an On-X aortic valve can be maintained safely and effectively on the factor Xa inhibitor apixaban.

Device Trials


  • IMPERIAL: A randomized trial comparing the ELUVIA™ drug-elutIng stent versus Zilver® PTX® stent for treatment of superficial femoral and/or proximal popliteal arteries.


  • PRESERVE II: Clinical study to evaluate the safety and effectiveness of Zenith Branch Endovascular Graft-Iliac Bifurcation.


  • PROACTIVE HF: Safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class III HF Patients.